WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.
CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.
NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.
ST Holdings (08305) issued a profit warning, expecting the comprehensive loss for the year 2025 to increase by no less than 19 million Hong Kong dollars compared to the previous year.
CLOVER BIO-B(02197): Clover Hong Kong has entered into a settlement agreement with the Global Vaccine Immunization Alliance.
NEW GONOW RV (00805) is expected to have a net profit of approximately 31 to 40 million yuan in the fiscal year 2025, a year-on-year decrease of about 12.07% to 31.85%.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
